טוען...
Current status of bevacizumab in advanced ovarian cancer
Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible ta...
שמור ב:
| Main Authors: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3724566/ https://ncbi.nlm.nih.gov/pubmed/23901283 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S46301 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|